General Updates

September 15, 2026 The Manager- Listing BSE Limited P J Towers, Dalal Street, Fort, Mumbai – 400 001 The Manager- Listing National Stock Exchange of India Limited Exchange Plaza, Bandra –Kurla Complex, Bandra (E), Mumbai – 400 051 Dear Sirs/ Madam, Sub: Information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Resignation of Senior Management Personnel Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we hereby inform that Dr. Sandeep Arora, Director – Medical Affairs, Biopharmaceutical Business Unit and Rare Disease Business Unit, of AstraZeneca Pharma India Limited (“the Company”) has decided to pursue a career outside the organization. Dr. Arora will complete his handover period and be relieved from duties by the close of business hours on September 15, 2026. We wish him all the best for his future endeavors. A copy of the resignation letter is enclosed herewith as Annexure – A. The Company is in the process of looking for a suitable replacement for this position. This being Senior Management Personnel position in terms of the SEBI Listing Regulations, please find the details as required under the SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/ 2026 dated January 30, 2026, attached herewith as Annexure – B. Kindly take the above information on record. Thanking you, For AstraZeneca Pharma India Limited Tanya Sanish Company Secretary & Compliance Officer Annexure - A Date: 15.09.2026 The Managing Director AstraZeneca Pharma India Limited Bangalore, India Dear Sir, Subject: Letter of Resignation I hereby subrnit my resignation from the position of Medical Director BBU & RDBU AstraZeneca Pharma India Linited, effeciive close of business hours on Septermber 15, 2026, to pursue career opportunities outside the organisation. Iw ould like to thank the senior managemernt and my colleagues for their support extended to me during my tenure with the Company and I wish AstraZeneca all the success in its future endeavours. Sincerely, eep Arora Medical Director BBU& RDBU Annexure - B Sl. Particulars Details 1. N ame & Designation Dr. Sandeep Arora, Director –Medical Affairs, Biopharmaceutical Business Unit and Rare Disease Business Unit 2. R eason for change Resignation to pursue his career outside the Company 3. D ate of cessation Effective close of business hours on September 15, 2026 4. T erm of appointment Not applicable 5. B rief Profile Not applicable